Peripheral Neuropathy Treatment Market By Treatment Type (Anticonvulsants, Antidepressants, Topical Analgesics, Non-Opioid Sodium-Channel Inhibitors, Opioid Analgesics, Spinal Cord Stimulation Devices, Peripheral Nerve Stimulation Devices, Physical Therapy and Rehabilitation, Nerve-Regeneration Therapies); By Application (Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Entrapment and Compression Neuropathy, Drug-Induced Peripheral Neuropathy, Autoimmune and Inflammatory Neuropathy, Nutritional Deficiency-Associated Neuropathy, Hereditary Peripheral Neuropathy); By End User (Hospitals, Neurology Clinics, Pain Management Clinics, Oncology Centers, Diabetes Care Centers, Ambulatory Surgical Centers, Physiotherapy and Rehabilitation Centers, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Peripheral Neuropathy Treatment Market: Refractory Pain and Nerve-Repair Programs Challenge Generic Drug Cycling

The Global Peripheral Neuropathy Treatment Market was valued at USD 2.64 billion in 2025 and is projected to reach USD 4.18 billion by 2032, growing at a CAGR of 6.8%, according to Strategic Market Research.

 

The Peripheral Neuropathy Treatment Market remains heavily dependent on low-cost medicines that reduce pain without repairing nerve damage. Gabapentin accounts for most first-line use in painful diabetic neuropathy, while pregabalin, duloxetine, tricyclic antidepressants, topical agents, and opioids fill the remaining treatment pathway. Frequent discontinuation, limited dose escalation, and incomplete pain relief weaken the clinical value of high prescription volume.

 

Higher spending is concentrated among patients who fail oral medicines and move into specialist care. High-concentration topical systems, spinal cord stimulation, pain-clinic services, and new non-opioid mechanisms generate substantially more revenue per patient than generic monthly prescriptions. Vertex’s suzetrigine and Lexicon’s pilavapadin are testing whether new oral drugs can reduce repeated switching among gabapentinoids and antidepressants. WinSanTor is pursuing nerve regeneration through WST-057, while chemotherapy-induced peripheral neuropathy remains a distinct specialty opportunity with no established preventive drug.

 

Global diabetic neuropathy cases reached approximately 206 million in 2021, more than three times the 1990 level. Pain status, diagnosis, previous treatment failure, specialist access, and reimbursement narrow that large epidemiological population into a much smaller treated market.

 

Diabetes Creates the Largest Patient Base, but Pain Determines Drug Use

The global diabetes population rose from approximately 200 million people in 1990 to 930 million in 2024. More than half were not taking diabetes medication, with the widest treatment gaps in low- and middle-income countries. Poor glucose control increases exposure to nerve damage, foot ulceration, falls, and amputation, but most people with diabetes will never enter a premium neuropathic-pain treatment pathway.

One-third to one-half of people with diabetes develop peripheral neuropathy, depending on disease duration, metabolic control, age, kidney function, and diagnostic method. Many experience numbness, loss of protective sensation, balance impairment, or asymptomatic nerve damage rather than painful symptoms. Painful diabetic neuropathy drives demand for gabapentinoids, antidepressants, topical analgesics, and neuromodulation. Non-painful disease generates spending through podiatry, foot surveillance, protective footwear, rehabilitation, ulcer prevention, and amputation avoidance.

Healthcare costs rise sharply after neuropathy becomes painful. A U.S. analysis estimated incremental annual all-cause costs of USD 3,093 for diabetic peripheral neuropathy without documented pain, USD 9,349 for painful disease, and USD 20,887 for severe painful neuropathy compared with diabetes without DPN. Prescriptions and inpatient care accounted for more than half of the additional spending in the painful groups.

Payers have a stronger reason to reimburse treatments that reduce hospital use, falls, ulcer complications, sleep disruption, and repeated medication changes than products supported only by small improvements in pain scores. Functional outcomes and healthcare-resource use will carry greater weight as device manufacturers and branded-drug companies seek premium reimbursement.

 

Generic Monotherapy Dominates, but Treatment Is Rarely Optimized

A U.S. analysis of 22,955 patients with painful diabetic neuropathy found that 98.5% began treatment with one medicine. Gabapentin accounted for 59.0% of initial prescriptions, followed by tramadol at 15.1%, oxycodone at 7.0%, pregabalin at 5.3%, and duloxetine at 5.2%. Generic medicines and opioids therefore remain more common at treatment initiation than newer branded or interventional options.

Recorded doses were frequently below recommended therapeutic ranges. Approximately 79% of gabapentin users, 91% of pregabalin users, and 61% of duloxetine users remained below recommended doses. Between 81% and 96% of patients had no recorded titration. More than three-quarters discontinued initial treatment within one year, with most discontinuations occurring during the first three months. Fewer than 35% of patients who stopped treatment switched to another pain medicine.

Sedation, dizziness, cognitive effects, weight gain, renal-dose restrictions, slow titration, and limited early relief discourage dose escalation. Primary-care physicians may also stop pharmacological treatment after one poor response rather than change drug class or combine two partially effective medicines.

The American Academy of Neurology recommends tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and sodium-channel blockers for painful diabetic neuropathy. Patients who receive inadequate relief from one class should generally try a different class rather than another medicine with the same mechanism. AAN also advises against initiating opioids, including tramadol and tapentadol, because long-term safety risks outweigh the evidence for durable benefit.

Tramadol and oxycodone still accounted for more than one-fifth of first prescriptions in the U.S. real-world study. A new oral non-opioid medicine could displace part of that use, but commercial success will require faster onset, lower discontinuation, fewer cognitive adverse effects, and reliable efficacy in patients already receiving gabapentin, pregabalin, or duloxetine.

 

Localized Treatment Carries More Pricing Power Than Oral Generics

Gabapentin will retain prescription leadership because it is inexpensive, familiar, and widely available. Clinical evidence supports substantial relief in a minority of patients rather than broad pain elimination. Pregabalin and duloxetine follow the same pattern: meaningful benefit for selected patients without restoration of damaged sensory fibres.

Generic competition limits pricing across systemic treatment. Extended-release formulations, simpler dosing, and improved tolerability can create modest differentiation, but payers have little reason to fund a large premium while several inexpensive classes remain available.

High-concentration topical capsaicin offers a more defensible treatment model. Qutenza is approved in the United States for neuropathic pain associated with diabetic peripheral neuropathy of the feet and has broader peripheral-neuropathic-pain positioning in Europe. Clinician administration shifts revenue away from daily retail prescriptions and into repeat in-office procedures. Limited systemic exposure also appeals to patients with polypharmacy or poor tolerance of oral medicines.

Grünenthal has extended Qutenza through regional licensing rather than building fully owned commercial teams in every market. Australian and South Korean agreements signed in 2026 broaden access while allowing local partners to manage distribution, reimbursement, and specialist promotion.

Application time, treatment-site discomfort, clinic access, and reimbursement will prevent high-concentration capsaicin from replacing generic first-line therapy. Strongest uptake is likely among patients with localized pain, systemic-drug intolerance, polypharmacy, or incomplete response to oral medicines.

 

Spinal Cord Stimulation Creates the Highest-Value Refractory DPN Segment

Implantable spinal cord stimulation has moved refractory painful diabetic neuropathy into neuromodulation clinics and ambulatory procedure settings. FDA-expanded indications now cover Nevro’s 10-kHz Senza platform, Abbott’s Proclaim systems, and selected Boston Scientific devices, giving pain specialists several implant options for chronic lower-limb pain that remains uncontrolled after medical treatment.

The SENZA-PDN randomized trial enrolled 216 patients whose pain remained inadequately controlled despite gabapentinoids and at least one additional analgesic class. The primary endpoint was achieved by 79% of patients receiving 10-kHz stimulation plus conventional treatment, compared with 5% receiving conventional treatment alone. At six months, 85% of implanted patients achieved at least 50% pain relief, versus 5% of controls. Infections requiring device removal occurred in 2% of the stimulation group.

Twenty-four-month follow-up reported a mean pain reduction of 79.9%, with 90.1% of retained participants achieving at least 50% relief. Durable response is critical because the implant, procedure, programming, and follow-up costs must be justified over several years. Results from retained trial participants should not be applied to every patient with diabetic neuropathy because implant candidates undergo strict clinical and psychological selection.

Globus Medical acquired Nevro in April 2025 for approximately USD 250 million. Nevro contributed USD 193.8 million in revenue between the acquisition date and September 2025 and USD 99.7 million during the fourth quarter. Globus can place the HFX and Senza portfolio within a larger spine and musculoskeletal sales organization with existing hospital, surgeon, and ambulatory-surgery relationships.

Abbott and Boston Scientific prevent the category from becoming a single-platform market. Device competition will depend on clinical evidence, waveform flexibility, battery performance, physician training, programming support, payer authorization, and post-implant service. Manufacturers that move eligible patients from repeated medication failure into implant evaluation can capture considerably more revenue per patient than suppliers of generic oral therapies.

 

Chemotherapy-Induced Neuropathy Remains a Specialty Treatment Gap

Chemotherapy-induced peripheral neuropathy occurs after taxanes, platinum drugs, vinca alkaloids, proteasome inhibitors, and other neurotoxic treatments. A meta-analysis of 31 studies and 4,179 patients estimated prevalence at 68.1% during the first month after chemotherapy, 60.0% at three months, and 30.0% at six months or later. Persistent disease extends treatment demand well beyond active oncology care.

Nearly 20 million new cancer cases were recorded worldwide in 2022, with annual incidence projected to reach approximately 35 million by 2050. Only patients exposed to neurotoxic therapy contribute to the CIPN population, but rising cancer incidence and longer survival increase the number living with chronic pain, sensory loss, impaired balance, and reduced hand function.

CIPN also affects the delivery of oncology treatment. Severe neuropathy can force dose reduction, treatment delay, drug substitution, or chemotherapy discontinuation. A preventive therapy could preserve planned treatment intensity while reducing long-term neurological complications.

ASCO has not identified a medicine with enough evidence for routine CIPN prevention. Duloxetine remains the only pharmacological option with adequate evidence for established painful CIPN, and its average benefit is modest.

AlgoTherapeutix tested ATX01, a 15% topical amitriptyline formulation, in the 276-patient Phase II ACT study. The trial did not achieve overall separation from placebo because several centres recorded unusually high placebo responses. Encouraging post-hoc findings at lower-placebo sites may support another study, but the failed primary endpoint prevents the company from treating those analyses as confirmatory evidence.

CIPN trials remain difficult because chemotherapy exposure, neuropathy phenotype, baseline analgesic use, cancer type, and placebo response vary across sites. Objective sensory measures and biomarkers may improve patient selection, but most mechanistic evidence still comes from preclinical models. Regulatory success will require prospectively defined endpoints and consistent performance across a large multicentre population.

 

Suzetrigine and Pilavapadin Aim to Replace Repeated Generic Switching

Vertex’s suzetrigine has the strongest operating position among late-stage oral candidates. FDA approval of Journavx for moderate-to-severe acute pain in January 2025 established NaV1.8 inhibition as a commercial non-opioid drug class. The acute-pain indication does not establish efficacy in chronic neuropathy, but it gives Vertex manufacturing capacity, payer experience, safety exposure, and an existing prescriber base before a possible DPN launch.

Vertex initiated two large Phase III studies in painful diabetic peripheral neuropathy. Each trial was designed to enroll approximately 1,100 patients and compare suzetrigine with placebo, with pregabalin included as a secondary comparator. The company expected both studies to complete enrollment by the end of 2026.

DPN patients may require treatment for years and often have kidney disease, cardiovascular disease, obesity, and extensive polypharmacy. Chronic-use tolerability and persistence will matter more than the short treatment courses used in acute-pain studies. Suzetrigine will need to provide durable relief without the sedation, cognitive effects, and titration burden that limit current medicines.

Lexicon’s pilavapadin offers a separate non-opioid mechanism through AAK1 inhibition. The Phase IIb PROGRESS study enrolled 496 adults and allowed one stable background neuropathy medicine, reflecting how a new drug may be used in practice as an addition to partial relief rather than as a complete replacement. The 10-mg dose showed improvement on several pain measures and was selected for Phase III development.

FDA raised no objection in January 2026 to two proposed 12-week registrational trials comparing pilavapadin 10 mg with placebo. Lexicon still faces financing and execution risk because the Phase II evidence includes nominal and post-hoc findings rather than an unambiguous pivotal result.

Vertex can fund two large trials internally and support a potential launch through an existing pain franchise. Lexicon may need a development or commercialization partner. Pilavapadin’s value will depend on clean Phase III evidence rather than mechanism novelty.

 

Nerve-Regeneration Programs Require Functional Proof

WinSanTor’s WST-057 is being developed to repair peripheral nerves rather than suppress pain signalling. The topical program has completed Phase I and Phase II work, with the company preparing two large Phase III studies in diabetic peripheral neuropathy. Early studies assessed intraepidermal nerve-fibre density and reported acceptable tolerability during treatment lasting up to six months.

A therapy that restores nerve function could reach both painful and non-painful neuropathy, giving it a larger eligible population than conventional analgesics. Payers and clinicians will still require evidence that nerve-fibre changes translate into restored sensation, improved balance, fewer ulcers, lower pain, or reduced amputation risk.

Phase III studies may need several thousand patients because nerve regeneration develops slowly and biopsy measurements vary between sites and laboratories. WST-057 therefore carries a larger development burden than a 12-week analgesic trial.

Other neuroprotection and regeneration programs remain earlier. Paeoniflorin has been proposed as a candidate based on anti-inflammatory, mitochondrial, oxidative-stress, and neuroprotective effects, but limited exposure and the absence of late-stage human evidence prevent near-term commercial inclusion.

 

Regional Market Direction

North America offers the strongest economics for premium treatment. Generic step therapy remains the entry point, but FDA-approved spinal cord stimulation, Qutenza, specialist pain networks, and large Phase III programs support higher spending after oral-treatment failure. Insurer authorization and access to trained implanters remain the main barriers to device adoption.

Europe provides broader use of topical capsaicin across peripheral neuropathic pain and stronger national control over treatment sequencing. New oral medicines will need comparative value against inexpensive generics, while neuromodulation uptake will vary with country-level reimbursement and specialist capacity.

Asia carries the largest diabetes-related patient ceiling but the widest variation in treatment access. High-volume markets favour generic gabapentin, pregabalin, duloxetine, and local pain services. Premium topicals and implants will remain concentrated in urban private-care systems until reimbursement and specialist infrastructure expand.

 

Competitive Positioning

Generic manufacturers will retain prescription leadership, but low dosing and early discontinuation restrict revenue per patient and leave substantial unmet need. Grünenthal holds a differentiated localized-treatment position through Qutenza and is extending geographic reach through regional licensing.

Globus Medical controls the most visible high-frequency stimulation platform after acquiring Nevro. Abbott and Boston Scientific provide scale-based competition through broader neuromodulation portfolios and established hospital access.

Vertex holds the strongest late-stage pharmaceutical position through suzetrigine, an approved acute-pain franchise, and two large DPN pivotal studies. Lexicon offers a differentiated AAK1 mechanism but carries greater financing and clinical-execution risk. WinSanTor has the highest disease-modification potential, although nerve-regeneration claims require larger and longer studies than standard pain programs. AlgoTherapeutix retains a possible CIPN route, but ATX01’s failed primary endpoint materially increases development risk.

 

Analyst Insight

Peripheral neuropathy treatment is dividing into a high-volume generic segment and a smaller high-value refractory segment. Generic medicines will remain difficult to displace at treatment initiation, but poor titration, opioid exposure, early discontinuation, and incomplete pain relief leave room for better oral drugs, localized therapy, and neuromodulation.

Spinal cord stimulation has already shown that selected refractory DPN patients can support implant-level spending when relief remains durable. Suzetrigine and pilavapadin must now show that new oral mechanisms can improve persistence and reduce medication cycling.

WST-057 could broaden treatment beyond painful neuropathy if nerve-fibre regeneration produces measurable functional recovery. CIPN remains the clearest specialty opportunity because prevention is absent and established treatment provides limited relief.

Therapeutic-dose attainment, one-year discontinuation, opioid initiation, Phase III progress for suzetrigine and pilavapadin, spinal cord stimulation coverage, implant volume, CIPN prevention outcomes, and functional evidence from nerve-regeneration studies will determine competitive performance. Products that reduce treatment failure or restore nerve function will capture more value than therapies offering another small reduction in pain score.

 

Peripheral Neuropathy Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.64 Billion
Revenue Forecast in 2032	USD 4.18 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Anticonvulsants, Antidepressants, Topical Analgesics, Non-Opioid Sodium-Channel Inhibitors, Opioid Analgesics, Spinal Cord Stimulation Devices, Peripheral Nerve Stimulation Devices, Physical Therapy and Rehabilitation, Nerve-Regeneration Therapies
By Application	Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Entrapment and Compression Neuropathy, Drug-Induced Peripheral Neuropathy, Autoimmune and Inflammatory Neuropathy, Nutritional Deficiency-Associated Neuropathy, Hereditary Peripheral Neuropathy
By End User	Hospitals, Neurology Clinics, Pain Management Clinics, Oncology Centers, Diabetes Care Centers, Ambulatory Surgical Centers, Physiotherapy and Rehabilitation Centers, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa, and others
Market Drivers	• Rising prevalence of diabetic and chemotherapy-induced peripheral neuropathy cases globally. • Increasing adoption of advanced neuromodulation devices and non-opioid pain management approaches. • Growing demand for personalized rehabilitation programs and nerve-regeneration therapies.
Customization Option	Available upon request